Daniel Faga
CIK 1673528 · President, CEO · last filed 2026-08-18
Daniel Faga is a President, CEO who has filed 42 SEC Form 4 insider transactions across 4 companies since 2016. The most recent filing, for TRAX, was dated Aug 18, 2026. Across all open-market trades the lifetime net is −$9.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $46.3M across reported positions. 20 SEC filings were submitted jointly with ANAPTYSBIO, INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ANAB price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 1300
PHILADELPHIA, PA 19104
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TRAX | President, CEO | 496,684 | $43.48 | $21.60M | $0 | 4 | 2026-08-18 |
| ANAB | President, CEO | 505,862 | $48.77 | $24.67M | -$6.34M | 17 | 2026-08-07 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | EVP, Chief Operating Officer | 30,638 | $58.70 | $1.80M | -$828.3K | 4 | 2021-02-03 |
| Spark Therapeutics, Inc. (ONCE) Delisted | Chief Business Officer | 0 | — | — | -$2.23M | 14 | 2019-12-17 |
Recent Filings
42 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-18 | TRAX | Grant (A) | — | $0 | EDGAR |
| 2026-08-07 | ANAB | Grant (A) | — | $0 | EDGAR |
| 2026-08-07 | ANAB | Grant (A) | — | $0 | EDGAR |
| 2026-08-05 | TRAX | Grant (A) | — | $0 | EDGAR |
| 2026-05-14 | TRAX | Grant (A) | — | $0 | EDGAR |
| 2026-04-23 | ANAB | Disp (D) | — | $0 | EDGAR |
| 2026-04-22 | ANAB | Mixed | — | $0 | EDGAR |
| 2026-04-22 | TRAX | Grant (A) | — | $0 | EDGAR |
| 2026-03-27 | ANAB | Mixed | +16,621 | -$1.09M | EDGAR |
| 2026-01-09 | ANAB | Mixed | +12,557 | -$638.5K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.